unfortunately did not put up here, but it had to do with the ratios in these studies. You know, it was the old 75-75 rule, which I don't mean to impose on this, but I'd like to point out that 80 to 90 percent of the patients, subjects rather, 24 in each of the studies, had ratios that were between 75 and a 125 percent. Most of them were between 80 and 120 percent. That's individual ratios and somebody can say, well, 80 percent, that's 20 percent off, but when you see 80 to 120 percent, that's including the variability of the assay, the biological variability. So, if we see individual ratios between 80 to 120 percent, we have a terrific product and that's what I saw for this product.
DR. KIBBE: Thank you, Sanford.
Our last speaker, Dr. Bill Barr.
DR. BARR: Good morning. I'll try to be brief. I know everybody is hungry.
Like some of the other speakers -- by the way, my name is Bill Barr. I'm Director of the Center for Drug Studies at the Virginia Commonwealth University, and as such, I receive money from almost everybody.